SLC5A1 and type 2 diabetes mellitus: Sotagliflozin is a novel dual SGLT1/SGLT2 inhibitor, which reduced total fatal or non-fatal stroke (HR: 0.66; 95%CI 0.48–0.91) in a post hoc analysis in persons with type 2 diabetes and chronic kidney disease [26].